TABLE 4.
Group | Weight (g) | |||||
0 weeks | 1 week | 2 weeks | 3 weeks | 4 weeks | Weight Gain | |
NC | 31.79 ± 1.50 | 31.93 ± 1.06 | 33.24 ± 1.07 | 33.92 ± 1.35 | 34.29 ± 1.68 | 2.50 ± 0.72 |
D–gal | 32.33 ± 1.26 | 33.27 ± 2.35 | 33.40 ± 2.32 | 34.42 ± 2.18 | 34.00 ± 1.95 | 1.67 ± 0.23 |
SL | 32.97 ± 0.81 | 33.57 ± 1.16 | 34.22 ± 1.66 | 34.29 ± 1.58 | 34.90 ± 2.66 | 1.93 ± 0.99 |
SM | 30.76 ± 1.13 | 31.40 ± 1.28 | 31.73 ± 1.77 | 32.33 ± 2.17* | 32.86 ± 2.01 | 2.10 ± 0.26 |
SH | 31.50 ± 0.79 | 32.02 ± 0.91 | 32.39 ± 0.94 | 33.14 ± 1.43 | 34.17 ± 1.31 | 2.67 ± 0.72* |
Vc | 31.40 ± 0.75 | 32.29 ± 1.48 | 32.88 ± 1.60 | 33.07 ± 1.43 | 34.31 ± 1.40 | 2.91 ± 0.86* |
Compared with D–gal group, *: p < 0.05. NC, normal control group; D–gal, D–gal model group; SL, low–dose SDE, group; SM, medium–dose SDE, group; SL, high–dose SDE, group; Vc, Vc positive control group.